Guardant Health, Ohio State University Partner on Blood-Based Colon Cancer Screening Study
OSU investigators will offer the Guardant Shield assay to patients via mobile phlebotomists, studying adoption rates among approximately 300 individuals.
Mainz Biomed Partners With Labor Staber to Market ColoAlert Test
Labor Staber will market the colorectal cancer screening kit through its network of physicians and laboratories in Germany.
Neogap Therapeutics, Simsen Diagnostics Collaborate on Cancer Dx
The companies will examine circulating tumor DNA in blood samples from patients participating in Neogap's Phase I/II clinical trial.
Guardant Health Submits Colorectal Cancer Screening Test to FDA for Premarket Approval
The firm's application is supported by data from the ECLIPSE study, which compared results of the Shield test to colonoscopy findings in 20,000 individuals.
Biocartis Nabs FDA 510(k) Clearance for Lynch Syndrome Screening Assay
The Idylla MSI Test identifies microsatellite instability in colorectal cancer tumors to aid in the identification of potential Lynch syndrome.